Paul Workman Selected Research

tanespimycin (17AAG)

11/2018	Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
5/2014	E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells.
11/2013	Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX.
8/2013	Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.
5/2012	Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
2/2012	A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
1/2012	Hsp90 molecular chaperone inhibitors: are we there yet?
3/2009	Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
10/2008	An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
4/2008	BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul Workman Research Topics

Disease

173	Neoplasms (Cancer) 01/2022 - 01/2002
16	Melanoma (Melanoma, Malignant) 01/2018 - 10/2006
14	Carcinoma (Carcinomatosis) 11/2013 - 01/2004
13	Colonic Neoplasms (Colon Cancer) 01/2018 - 06/2002
12	Glioblastoma (Glioblastoma Multiforme) 10/2017 - 03/2009
9	Ovarian Neoplasms (Ovarian Cancer) 11/2018 - 07/2002
7	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2002
6	Prostatic Neoplasms (Prostate Cancer) 12/2021 - 03/2011
6	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 10/2003
6	Carcinogenesis 12/2016 - 01/2004
6	Hypoxia (Hypoxemia) 06/2011 - 07/2002
4	Glioma (Gliomas) 09/2009 - 06/2007
4	Neoplasm Metastasis (Metastasis) 04/2008 - 01/2002
3	Neuroblastoma 11/2020 - 11/2011
3	Cholangiocarcinoma 01/2020 - 01/2017
2	Chordoma 01/2021 - 01/2019
2	Leukemia 01/2020 - 11/2004
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 10/2012
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 06/2014
2	Circulating Neoplastic Cells 01/2019 - 09/2009
2	Fatigue 01/2019 - 10/2008
2	Disease Progression 10/2017 - 06/2009
2	Ovarian Epithelial Carcinoma 01/2015 - 03/2008
2	Multiple Myeloma 10/2013 - 01/2012

Drug/Important Bio-Agent (IBA)

60	Pharmaceutical PreparationsIBA 01/2021 - 01/2002
43	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2002
29	Heat-Shock Proteins (Heat-Shock Protein)IBA 11/2018 - 01/2002
26	Biomarkers (Surrogate Marker)IBA 01/2020 - 04/2005
25	Molecular Chaperones (Chaperone, Molecular)IBA 01/2020 - 01/2002
21	tanespimycin (17AAG)IBA 11/2018 - 01/2002
20	Phosphotransferases (Kinase)IBA 01/2019 - 10/2004
16	Biological ProductsIBA 01/2020 - 10/2003
9	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2020 - 01/2004
9	Phosphorylcholine (Phosphocholine)IBA 07/2017 - 11/2003
8	PI103IBA 01/2017 - 06/2007
8	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 08/2013 - 10/2006
7	Oncogene Proteins (Oncogene Protein)IBA 01/2020 - 01/2002
6	Transcription Factors (Transcription Factor)IBA 01/2021 - 01/2012
6	Adenosine Triphosphate (ATP)IBA 01/2020 - 04/2009
6	RoscovitineIBA 01/2018 - 01/2004
6	Protein Isoforms (Isoforms)IBA 05/2017 - 09/2008
6	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2014 - 01/2006
6	Adenosine Triphosphatases (ATPase)IBA 01/2012 - 06/2004
5	Temozolomide (Temodar)FDA LinkGeneric 11/2020 - 02/2009
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 04/2005
5	Lactic Acid (Lactate)FDA LinkGeneric 07/2017 - 07/2013
5	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA 01/2016 - 09/2008
5	Phosphorus (Red Phosphorus)IBA 01/2014 - 11/2003
4	RNA (Ribonucleic Acid)IBA 12/2021 - 10/2003
4	LigandsIBA 12/2021 - 03/2007
4	Choline (Choline Chloride)IBA 01/2017 - 01/2006
4	Protons (Proton)IBA 01/2014 - 11/2003
4	DNA (Deoxyribonucleic Acid)IBA 01/2014 - 12/2007
4	Aurora KinasesIBA 10/2012 - 05/2004
4	EnzymesIBA 09/2012 - 05/2004
4	LAQ824IBA 02/2012 - 08/2006
4	Histone Deacetylase InhibitorsIBA 02/2012 - 08/2006
4	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 01/2012 - 01/2008
4	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2012 - 09/2008
4	Imatinib Mesylate (Gleevec)FDA Link 09/2009 - 12/2003
3	ErbB Receptors (EGF Receptor)IBA 12/2021 - 05/2009
3	MicroRNAs (MicroRNA)IBA 11/2021 - 01/2007
3	Drug CombinationsIBA 01/2019 - 05/2012
3	Amino Acids FDA Link 10/2017 - 04/2009
3	MTOR InhibitorsIBA 07/2017 - 01/2016
3	Messenger RNA (mRNA)IBA 07/2017 - 02/2006
3	ProteomeIBA 01/2016 - 12/2009
3	Protein Kinases (Protein Kinase)IBA 11/2015 - 09/2008
3	Histones (Histone)IBA 05/2013 - 05/2004
3	Choline KinaseIBA 05/2012 - 01/2006
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2012 - 07/2002
3	LipidsIBA 01/2012 - 06/2007
3	Complementary DNA (cDNA)IBA 03/2011 - 02/2004
3	Phospholipids (Phosphatides)FDA LinkGeneric 07/2010 - 11/2003
3	Cytotoxins (Cytolysins)IBA 06/2009 - 05/2005
3	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 03/2007 - 12/2005
3	geldanamycinIBA 03/2006 - 01/2002
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2021 - 10/2004
2	Irinotecan (Camptosar)FDA LinkGeneric 11/2021 - 10/2004
2	Fluorouracil (Carac)FDA LinkGeneric 11/2021 - 10/2003
2	Brachyury protein (Brachyury)IBA 01/2021 - 01/2019
2	CYC065IBA 11/2020 - 01/2020
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 07/2002
2	Androgen Receptors (Androgen Receptor)IBA 01/2019 - 01/2016
2	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 01/2019 - 01/2016
2	Carboplatin (JM8)FDA LinkGeneric 11/2018 - 10/2008
2	Antineoplastic Agents (Antineoplastics)IBA 01/2018 - 09/2011
2	Phosphatidylcholines (Phosphatidylcholine)IBA 10/2017 - 01/2016
2	VemurafenibIBA 12/2016 - 01/2013
2	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 04/2016 - 09/2008
2	Mediator ComplexIBA 02/2016 - 12/2015
2	Hormones (Hormone)IBA 01/2016 - 11/2015
2	N-Myc Proto-Oncogene ProteinIBA 01/2016 - 11/2011
2	Ribosomal Proteins (Ribosomal Protein)IBA 01/2015 - 05/2010
2	Small Interfering RNA (siRNA)IBA 05/2014 - 02/2009

Therapy/Procedure

47	Therapeutics 01/2022 - 01/2002
11	Drug Therapy (Chemotherapy) 11/2021 - 10/2004
4	Precision Medicine 01/2022 - 12/2006
4	Castration 12/2021 - 03/2011
3	Radiotherapy 07/2017 - 06/2011